# FDA proposes to exclude weight-loss drugs of Novo Nordisk and Eli Lilly from critical compounding list.

*biotech · news · 2026-04-30 · Devdiscourse*

## Key points

- The FDA proposes to exclude Novo Nordisk and Eli Lilly weight-loss drugs from the 503B compounding list.
- This exclusion targets unauthorized compounded versions that affect sales of Wegovy, Ozempic, Zepbound, and Mounjaro.
- Novo Nordisk and Eli Lilly stocks surged by nearly 6% and over 10% respectively after the announcement.
- The FDA stated there is no clinical need for outsourcing facilities to compound these active ingredients.

**Companies:** Eli Lilly, Novo Nordisk
**Countries:** United States, Denmark

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3892735-fda-proposal-shakes-up-weight-loss-drug-market-for-novo-and-lilly)

---

Canonical: https://newsio.io/n/692fbd33-c9cb-44b7-9540-9b9d0c51f404/fda-proposes-to-exclude-weight-loss-drugs-of-novo-nordisk-and-eli-lilly-from-cri
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works